Crestline Management’s Heron Therapeutics HRTX Stock Holding History

Crestline Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-185,766	Closed	-$1.7M	–	289
2021 Q4	$1.7M	Buy	185,766 +82,921	+81%	+$847K	0.13%	120
2021 Q3	$1.1M	Buy	+102,845	New	+$1.25M	0.1%	128
2018 Q3	–	Sell	-75,645	Closed	-$2.94M	–	187
2018 Q2	$2.94M	Sell	75,645 -15,271	-17%	-$486K	0.31%	90
2018 Q1	$2.51M	Sell	90,916 -25,374	-22%	-$576K	0.31%	44
2017 Q4	$2.1M	Buy	116,290 +76,212	+190%	+$1.24M	0.22%	37
2017 Q3	$647K	Buy	40,078 +3,058	+8%	+$48K	0.09%	116
2017 Q2	$513K	Buy	+37,020	New	+$536K	0.07%	111

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Crestline Management's HRTX Position: Q1 2022 in Review

Crestline Management sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 185,766 shares — an estimated $1.7M sold.

Crestline Management first reported a position in HRTX in Q2 2017 and held it in 7 quarters. The position peaked at $2.94M in Q2 2018. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

Crestline Management reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
Crestline Management sold 185,766 Heron Therapeutics shares in Q1 2022, an estimated $1.7M.
Crestline Management first reported a position in Heron Therapeutics in Q2 2017 and held it in 7 quarters.
Crestline Management's Heron Therapeutics position peaked at $2.94M in Q2 2018.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Crestline Management's 13F filing for Q1 2022, filed 16 May 2022.